What non‑SSRI anxiolytic medication can be added for a patient already taking alprazolam (a benzodiazepine) along with the listed medications?

Pregabalin is the most appropriate non-SSRI anxiolytic to add for this patient already taking alprazolam

Given this patient is already on escitalopram (an SSRI) and alprazolam (a benzodiazepine), pregabalin represents the best evidence-based non-SSRI anxiolytic option for augmentation. 1

Rationale Based on Guidelines

The Canadian Clinical Practice Guideline explicitly lists pregabalin as a first-line agent for anxiety disorders, alongside SSRIs and SNRIs 1. This is particularly relevant because:

• Pregabalin has demonstrated anxiolytic efficacy without benzodiazepine-related risks of dependence, cognitive impairment, or respiratory depression
• It does not interact with alprazolam's metabolism (unlike SSRIs which can increase alprazolam levels via CYP3A inhibition) 2
• The patient is already on gabapentin 600 mg at bedtime, suggesting familiarity with this drug class and potential tolerability

Important Consideration: The Patient is Already on Gabapentin

Notably, this patient is already taking gabapentin 600 mg nightly, which is structurally similar to pregabalin and listed as a second-line anxiolytic 1. Before adding pregabalin:

• Consider optimizing the gabapentin dose first - the current 600 mg once-daily dosing may be subtherapeutic for anxiety (typical anxiolytic doses are 900-3600 mg/day divided)
• If gabapentin is being used solely for another indication (neuropathic pain, sleep), then pregabalin could be added specifically for anxiety at 150-600 mg/day divided

Alternative Non-SSRI Options (in descending order of evidence)

Buspirone (Azapirone)

• Partial serotonin agonist with no abuse potential, no sedation, and no withdrawal symptoms 3
• Takes 2-4 weeks for anxiolytic effect (unlike benzodiazepines)
• Critical caveat: Less effective in patients already exposed to benzodiazepines - this patient's chronic alprazolam use may limit buspirone's efficacy
• No drug interactions with current medications
• Typical dose: 15-60 mg/day divided

SNRIs (Venlafaxine, Duloxetine)

While technically serotonergic, SNRIs are not SSRIs and are listed as first-line agents 1:

• Venlafaxine is specifically recommended in multiple guidelines
• Important interaction warning: SNRIs can inhibit CYP3A and increase alprazolam levels, requiring alprazolam dose reduction 2
• May worsen anxiety initially (first 1-2 weeks)

Hydroxyzine (Antihistamine)

• Anxiolytic effects without benzodiazepine risks
• Sedating, which may be beneficial or problematic depending on timing
• No significant drug interactions with current regimen
• Typical dose: 25-100 mg divided or at bedtime

Critical Safety Concerns with Current Alprazolam Use

This patient's alprazolam regimen (0.25-1 mg as needed, max 1 mg/day) is relatively low-dose, but several FDA warnings are relevant 2:

• Escitalopram may increase alprazolam levels through CYP3A inhibition, though the clinical significance is uncertain 2
• Combining alprazolam with other CNS depressants (including gabapentin) increases sedation and respiratory depression risk 2
• Long-term benzodiazepine use should be avoided - consider a gradual taper plan while optimizing alternative anxiolytics 4, 5, 6

Practical Algorithm

1. First: Optimize gabapentin dosing for anxiety (increase to 900-1800 mg/day divided TID if tolerated and indicated for anxiety)
2. If inadequate response: Add pregabalin 75 mg BID, titrate to 150-300 mg BID as needed
3. Alternative if gabapentin/pregabalin contraindicated or ineffective: Buspirone 7.5 mg BID, titrate to 15-30 mg BID (acknowledge limited efficacy in benzodiazepine-exposed patients)
4. Concurrent strategy: Develop alprazolam taper plan (reduce by 0.25 mg every 1-2 weeks) once alternative anxiolytic is therapeutic 2

Common Pitfalls to Avoid

• Do not abruptly discontinue alprazolam - seizure risk with rapid withdrawal 2
• Do not add multiple CNS depressants simultaneously - this patient already has respiratory disease (on multiple inhalers) making respiratory depression particularly dangerous
• Do not expect immediate anxiolytic effect from buspirone - requires 2-4 weeks, unlike benzodiazepines
• Monitor for increased alprazolam effects if adding any CYP3A inhibitor